Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 10.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 927,017 shares of the company’s stock after buying an additional 90,822 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Day One Biopharmaceuticals were worth $11,745,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. raised its position in shares of Day One Biopharmaceuticals by 90.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 121,167 shares of the company’s stock worth $1,535,000 after purchasing an additional 57,601 shares during the period. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the 4th quarter worth $866,000. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals in the fourth quarter worth $31,000. China Universal Asset Management Co. Ltd. increased its position in Day One Biopharmaceuticals by 11.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock worth $271,000 after buying an additional 2,180 shares during the period. Finally, Handelsbanken Fonder AB lifted its stake in Day One Biopharmaceuticals by 16.7% in the fourth quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $399,000 after buying an additional 4,500 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $6.45 on Friday. The firm has a market cap of $653.73 million, a P/E ratio of -6.26 and a beta of -1.24. The stock’s 50-day moving average is $7.70 and its two-hundred day moving average is $11.10. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $6.26 and a fifty-two week high of $17.14.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. On average, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Activity

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,064 shares of company stock worth $251,925. Company insiders own 6.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC cut their price target on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, March 25th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Buy” and an average target price of $30.57.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.